Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma. Read more about Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma.
Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force. Read more about Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Read more about Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro.
Rapid progression of prostate cancer in men with a BRCA2 mutation. Read more about Rapid progression of prostate cancer in men with a BRCA2 mutation.
Parity and breastfeeding are protective against breast cancer in Nigerian women. Read more about Parity and breastfeeding are protective against breast cancer in Nigerian women.
Targeting HER proteins in cancer therapy and the role of the non-target HER3. Read more about Targeting HER proteins in cancer therapy and the role of the non-target HER3.
COX2 genetic variation, NSAIDs, and advanced prostate cancer risk. Read more about COX2 genetic variation, NSAIDs, and advanced prostate cancer risk.
Mechanisms of adverse effects of anti-VEGF therapy for cancer. Read more about Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy. Read more about Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy.
Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS. Read more about Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS.
